Reported Earlier, Taysha Gene Therapies Announces ~$200M Public Offering Of 32,500,001 Common Stock Shares At $6.00 Per Share And Pre-Funded Warrants

Benzinga Newsdesk www.benzinga.com Neutral 89.2%